Cemiplimab Can Improve PROs in NSCLC
Adding cemiplimab to first-line chemotherapy can improve patient-reported outcomes in non-small cell lung cancer, research suggests.
Adding cemiplimab to first-line chemotherapy can improve patient-reported outcomes in non-small cell lung cancer, research suggests.
A multidisciplinary treatment approach can produce favorable outcomes in patients with superior sulcus NSCLC, according to researchers.
Station 9 lymph nodes should be sampled for primary non-small cell lung cancer of the middle and lower lobes, according to researchers.
Patients with non-small cell lung cancer may have a 3-fold higher risk of death if they develop COVID-19, a study suggests.
Salvage resection may benefit patients with NSCLC who have residual or recurrent disease after immunotherapy, a study suggests.
Induction with alectinib or crizotinib is clinically feasible in ALK-positive, stage III non-small cell lung cancer, according to researchers.
Several groups of patients are underrepresented in NSCLC clinical trials, new research suggests.
Reductions in air pollutants coincided with reductions in lung cancer incidence in a Michigan county, researchers found.
Women are underrepresented in clinical trials of NSCLC treatment, a meta-analysis suggests.
Medicaid expansion was associated with a decrease in disparities among patients with non-small cell lung cancer, research suggests.